Optimization of CAR-T Cell-Based Therapies Using Small-Molecule-Based Safety Switches
- 30 June 2021
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 64 (14) , 9577-9591
Abstract
Chimeric antigen receptor T cell therapy has demonstrated antileukemia efficacy. However, this therapeutic approach is hampered by severe cytokine release syndrome, which is a major impediment to its widespread application in the clinic. The safety of this approach can be improved by engineering a rapid and reversible “off” or “on” safety switch for CAR-T cells. Cutting-edge investigations combining the advantages of genetic engineering and chemical technology have led to the invention of small-molecule-based safety switches for CAR-T cells. Small molecules such as FITC, folate, rimiducid, rapamycin, proteolysis-targeting chimera (PROTAC) compounds, and dasatinib are being investigated to design such safety switches. Optimized CAR-T cells may have enhanced therapeutic efficiency with fewer adverse effects. Herein we summarize and classify current novel small-molecule-based safety switches for CAR-T cells that aim to provide pharmacological control over the activities and toxicities associated with CAR-T cell-based cancer immunotherapies.Keywords
Funding Information
- Guangzhou Municipal Science and Technology Program key projects (201904010380)
- National Natural Science Foundation of China (81773558, 82073689)
- Natural Science Foundation of Guangdong Province (2018B030312010, 2020A151501518)
This publication has 91 references indexed in Scilit:
- Adoptive Cell Therapy—Harnessing Antigen-Specific T Cells to Target Solid TumoursCancers, 2020
- The market for chimeric antigen receptor T cell therapiesNature Reviews Drug Discovery, 2018
- Chimeric Antigen Receptor T Cells in Refractory B-Cell LymphomasNew England Journal of Medicine, 2017
- Tisagenlecleucel — the first approved CAR-T-cell therapy: implications for payers and policy makersNature Reviews Clinical Oncology, 2017
- Engineering CAR-T cellsBiomarker Research, 2017
- Chimeric Antigen Receptor T Cells for Sustained Remissions in LeukemiaNew England Journal of Medicine, 2014
- CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patientsJournal of Clinical Investigation, 2011
- Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapyExpert Opinion on Biological Therapy, 2011
- The promise and potential pitfalls of chimeric antigen receptorsCurrent Opinion in Immunology, 2009
- Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.Proceedings of the National Academy of Sciences of the United States of America, 1993